ValCare Medical
Minimally Invasive Treatment for Valve Disease
Company Overview
Snapshot
Founded in June 2012 by Samuel Shaolian, ValCare Medical operates with 11–50 employees. The company has raised $23M across three funding rounds from four investors. In May 2024, ValCare Medical announced the enrollment of the first two patients in its AMEND™ TS EU Pilot Study.
Business overview
ValCare Medical is a Health Tech & Life Sciences company focused on developing innovative minimally-invasive technologies for treating mitral and tricuspid regurgitation. Its product portfolio includes solutions for mitral valve repair and replacement, as well as tricuspid valve repair. The company's core technology is a D-shaped ring platform designed for mitral annulus repair, which also serves as a docking station for its proprietary replacement prosthesis. ValCare Medical serves the cardiology and medical device sectors, targeting surgeons and hospitals globally.
Strategic signal
In May 2024, ValCare Medical announced the enrollment of the first two patients in its AMEND™ TS EU Pilot Study. This milestone is significant as it marks a critical step in the clinical validation and potential market entry of its transseptal annuloplasty ring for mitral valve repair, signaling progress in its product development pipeline and future commercialization efforts to investors.
Log in to access full profile ›Company Intelligence Q&A
- What was the latest significant clinical development for ValCare Medical?
- In May 2024, ValCare Medical announced the enrollment of the first two patients in its AMEND™ TS EU Pilot Study, advancing the clinical evaluation of its transseptal annuloplasty ring for mitral valve repair.
- When did ValCare Medical announce a corporate restructuring and new CEO appointment?
- In April 2024, ValCare Medical Inc. announced a corporate restructuring and the appointment of a new CEO.
- When did ValCare Medical form its Scientific Advisory Board?
- In July 2024, ValCare Medical Inc. announced the formation of its Scientific Advisory Board, comprising renowned mitral valve experts.
- Which investors participated in ValCare Medical's funding round in November 2023?
- This funding round was a secondary round, contributing to the company's total of $23M raised across three funding rounds.
- When did ValCare Medical achieve its first-in-human transseptal implant of the AMEND annuloplasty ring?
- In January 2021, ValCare Medical announced the first-in-human transseptal implant of the AMEND™ Annuloplasty Ring for mitral valve repair.